Semustine

Reactive alkylating (chloroethyl-diazonium) and carbamylating (isocyanate) intermediates generated as semustine decomposes bind irreversibly to renal tubular and glomerular macromolecules. In Fischer-344 rat models a single dose caused early depression of proximal-tubule organic-anion (PAH) transport and concentrating ability that progressed to a chronic, largely irreversible nephropathy, and covalent binding/toxicity tracked hepatic biotransformation (a liver-derived metabolite appears to drive the renal injury). Glutathione is protective: buthionine-sulfoximine depletion of GSH markedly worsened nephrotoxicity, implicating a reactive electrophilic intermediate. In humans the end result is a slowly evolving chronic tubulointerstitial process, biopsies show tubular atrophy, interstitial fibrosis, and glomerulosclerosis, i.e., a scarring rather than an acute-necrosis lesion, that continues to progress even after the drug is stopped.

Insidious, largely asymptomatic azotemia: a slow rise in serum creatinine/BUN and falling GFR, characteristically with a bland urinary sediment and little or no proteinuria and no antecedent phase of acute renal failure. Imaging may show small, shrunken kidneys. Because urine studies stay unremarkable, the disease is often detected only on routine chemistry, sometimes long after therapy. Unlike streptozocin, prominent proximal-tubular wasting (RTA, phosphaturia, glucosuria) is not the dominant feature; the story is progressive CKD from tubulointerstitial and glomerular scarring, which can reach ESRD.

There is no specific antidote. Management is to permanently discontinue the drug and shift to supportive CKD care: blood-pressure control, RAAS blockade for proteinuric CKD, avoidance of further nephrotoxins and nephrotoxic contrast/NSAIDs, and early nephrology referral. Because the lesion is fibrotic and can progress despite stopping, the emphasis is on slowing progression rather than reversing it; advanced disease requires renal replacement therapy or transplantation. Experimental protectants (prochlorperazine, glutathione-repleting strategies) have only preclinical support and are not part of clinical care.Lesion-level management framework

Management is by cumulative-dose ceiling, not by per-level renal titration. Because the injury is delayed and cumulative, there is no validated GFR-banded dose-reduction schedule; instead, hold or permanently stop semustine at the first sustained creatinine rise and count exposure toward a lifetime nitrosourea limit (clinical toxicity clusters above ~1,200-1,400 mg/m2). Avoid initiating in patients with pre-existing significant CKD, and never re-challenge after documented nitrosourea nephrotoxicity.

Not meaningfully dialyzable and dialysis has no role in preventing the toxicity. Semustine is highly lipophilic, rapidly metabolized, and extensively tissue/protein-bound, so hemodialysis is not expected to remove parent drug or its short-lived reactive intermediates. Dialysis is relevant only as renal-replacement therapy for the resulting ESRD, not as an antidote.

Distinguish from other chronic tubulointerstitial/scarring nephropathies with bland urine: chronic injury from the sibling nitrosoureas (carmustine, lomustine, streptozocin) and cisplatin-associated CKD; radiation nephritis; analgesic/aristolochic and other chronic interstitial nephritides; and hypertensive or diabetic nephrosclerosis. The key discriminators are the heavy cumulative nitrosourea exposure, the delayed onset (often after therapy ends), and the near-absence of an acute-renal-failure phase or active sediment. Streptozocin, by contrast, favors a proximal-tubular (Fanconi/RTA, phosphaturia, proteinuria) picture.